LIXTE Biotechnology's Preclinical Results In Collaboration With Netherlands Cancer Institute Reveal Novel Mechanism By Which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness Of Immunotherapy And Chemotherapy
Portfolio Pulse from Happy Mohamed
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced that its lead clinical compound LB-100 has shown to enhance the effectiveness of immunotherapy and chemotherapy in preclinical studies. The studies, conducted in collaboration with the Netherlands Cancer Institute, revealed that LB-100 inhibits PP2A in colon cancer cells, leading to significant changes in mRNA processing. This results in the production of aberrant proteins that can be recognized by the immune system, making the cancer cells more sensitive to immunotherapy. The findings also suggest that LB-100 reduces the cancer cells' ability to deal with DNA damage, demonstrating synergy with radiotherapy and various chemotherapies.
July 17, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LIXTE Biotechnology's lead clinical compound LB-100 has shown promising results in preclinical studies, potentially enhancing the effectiveness of immunotherapy and chemotherapy. This could lead to increased investor interest in the company.
The positive preclinical results for LIXTE's lead compound LB-100 could potentially lead to increased investor interest in the company. The findings suggest that LB-100 could enhance the effectiveness of immunotherapy and chemotherapy, which are key treatments for cancer. This could potentially lead to increased demand for LB-100, boosting LIXTE's revenues and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100